T. Gorlia

Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

Martin J. van den Bent, Alba A. Brandes, Johan Menten et al. · Journal of Clinical Oncology · 2003 · 296 citations

Medicine, Oncology, Surgery +17

Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034

Martin J. van den Bent, A.A. Brandes, R. Rampling et al. · Journal of Clinical Oncology · 2007 · 53 citations

Medicine, Oncology, Pharmacology +17

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Ya Gao, Bas Weenink, Martin J. van den Bent et al. · European Journal of Cancer · 2018 · 39 citations

Medicine, Cancer Biology, Oncology +15

PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion

Martin J. van den Bent, Sara Erridge, Michael A. Vogelbaum et al. · Neuro-Oncology · 2019 · 29 citations · Full text

Medicine, Oncology, Radiation Oncology +17

A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)

R. Rampling, Marc Sanson, T. Gorlia et al. · Neuro-Oncology · 2012 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17